Investors braced for a bumpy ride ahead of Chemed's
What analysts say:
- Buy, sell, or hold?: Half of analysts think investors should stand pat on Chemed. Analysts like Chemed better than competitor Amedisys overall. One out of 11 analysts rate Amedisys a buy compared to two of six for Chemed. Analysts still rate the stock a Hold, but they are a bit more wary about it compared to three months ago.
- Revenue Forecasts: On average, analysts predict $353.5 million in revenue this quarter. That would represent a rise of 5.1% from the year-ago quarter.
- Wall Street Earnings Expectations: The average analyst estimate is earnings of $1.30 per share. Estimates range from $1.22 to $1.41.
What our community says:
CAPS All-Stars are solidly backing the stock, with 94.1% assigning it an "outperform" rating. The community at large is in line with the All-Stars, with 87.1% awarding it a rating of "outperform." Fools are bullish on Chemed, though the message boards have been quiet lately with only 36 posts in the past 30 days. Chemed's bearish CAPS rating of two out of five stars falls short of the Fool community sentiment.
Chemed's profit has risen year-over-year by an average of 7.8% over the past five quarters. Revenue has now gone up for three straight quarters.
Now let's look at how efficient management is at running the business. Traditionally, margins serve as an illustration of how efficiently a company captures portions of sales dollars. Chemed's gross margins have been decreasing year-over-year for the last four quarters. Gross margins reflect the total sales revenue retained after costs. Here are Chemed's reported margins for the last four quarters:
For all our Chemed-specific analysis, including earnings and beyond, add Chemed to My Watchlist.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Earnings estimates provided by Zacks.